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comments on our recently published article. We
agree this is important research that addressessome of the limitations of previous trials of the low FODMAP
diet, including our use of dietary advice as the intervention,
the use of a placebo-control group and detailed approaches
to ensure blinding.1 To clarify, 66% of participants in our
study had diarrhea-predominant irritable bowel syndrome
(IBS), and 34% had mixed or unsubtyped IBS (see Table 1).2
First, with regard to the individual symptoms that were a
priori secondary endpoints in our study. Our article dis-
cussed that the dichotomous primary outcome for symptoms
(adequate symptom relief) failed to achieve statistical sig-
niﬁcance between the low FODMAP and placebo diets (P ¼
.051). We also discuss the limitations of dichotomous end-
points and agree that individual symptom severity is
important, particularly in a condition often accompanied by
several symptoms. After correction formultiple comparisons,
IBS-SSS scores (total score, days of pain, distension severity,
and satisfaction with bowels) and severity of bloating, ﬂat-
ulence, and urgency (measured using the Gastrointestinal
Symptom Rating Scale) were signiﬁcantly lower after the low
FODMAP diet compared with placebo diet. These ﬁndings are
consistent with that of a recent meta-analysis demonstrating
abdominal pain and bloating are responsive to a low FOD-
MAP diet.3 The inclusion of multiple IBS subtypes in the
current study (including IBS-M) reduces the extent to which
an “improvement” in stool output can be demonstrated.
Second, the pointwas raised that therewas a possibility of
a placebo effect in both the low FODMAP and placebo diet
groups. All intervention groups in all randomized controlled
trials may be subject to a placebo effect, and the purpose of a
control group is not to eliminate the placebo effect but to
provide a comparator against which the intervention can be
assessed. The placebo effect in IBS is considerable, with a
systematic review and meta-analysis of pharmacotherapy
trials reporting a pooled placebo response in 37.5% of pa-
tients.4 We agree that a 38% response rate in our placebo
group was high, but is highly consistent with placebo
response rates in IBS, therefore, supportive of the suitability
of our sham diet as a placebo diet. Incorporating a placebo
diet in a randomized controlled trial is more challenging for
dietary interventions because there may be greater interac-
tion with researchers and blinding is inherently more difﬁ-
cult.5 A previous placebo-controlled feeding trial was central
in establishing that the low FODMAP diet was more effective
than placebo6 and our trial, using sham dietary advice as a
placebo intervention, considerably extend these by conﬁrm-
ing the clinical translatability of low FODMAP dietary advice
in practice. As in almost all randomized controlled trials, both
groups were aware they were being studied, but were un-
aware of allocation to active intervention or placebo.
In regard to the request for symptom data before the di-
etary intervention, our analysis used adjusted linear regres-
sion models that accounted for baseline differences between
groups. All patients completed 7-day symptoms diaries at
baseline and follow-up using the Gastrointestinal Symptom
Rating Scale, as outlined in the article.2 Requesting partici-
pants to record their symptoms for longer than this wouldhave been overly burdensome, considering the other study
requirements. We acknowledge ﬂuctuating symptom
severity in IBS is a challenge in clinical trials; however, with a
large enough sample size and randomization, it is expected
that differences in the severity and patterns of symptoms
would be evenly distributed across groups. In addition, we
incorporated exclusion criteria to ensure symptom severity
met a minimum recommended threshold.
Finally, a discussion of low gas diets described by Levitt
from the 1970s and 1990s was requested. These papers
examine the pathophysiology of abdominal pain or bloating
in individuals in the fasted state7 and after a ﬁber interven-
tion,8 and gas production in response to carbohydrates in
healthy individuals.9 Notwithstanding the importance of
these studies in providing the scientiﬁc underpinning of our
understanding of colonic carbohydratemetabolism, we chose
instead to cite a recent investigation using imaging tech-
niques measuring the effect of fermentable carbohydrates on
colonic gas in IBS because these outcomes related more
speciﬁcally to the clinical scenario under investigation.10
Furthermore, the scope of the current study was limited to
the clinical and microbiological impact of dietary interven-
tion in IBS, rather than an examination of the mechanisms.
We thank Professor Craig for highlighting the impor-
tance of control groups, blinding, and accounting for base-
line variations in symptom in trials of IBS, which we believe
are strengths of our published study.
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